Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Home > Insider Trading > Filing (0001209191-19-044881)

Filing Details

Accession Number:
0001209191-19-044881
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-08-06 18:14:32
Reporting Period:
2019-08-02
Accepted Time:
2019-08-06 18:14:32
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1660334 Verrica Pharmaceuticals Inc. VRCA Pharmaceutical Preparations (2834) 463137900
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1741937 Matt Davidson C/O Verrica Pharmaceuticals Inc.
10 North High Street, Suite 200
West Chester PA 19380		 No No Yes No
Reported Non-Derivative Transactions
Show Other Fields >>
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2019-08-02 1,969 $10.78 2,588,775 No 4 S Direct
Common Stock Disposition 2019-08-05 1,679 $10.65 2,587,096 No 4 S Direct
Common Stock Disposition 2019-08-06 2,602 $10.28 2,584,494 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.
  2. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.25 to $11.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.28 to $10.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.